Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alzheimer’s

- PMLiVE

Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm

Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its dealings with the company.

- PMLiVE

Mixed results for AC Immune’s promising Alzheimer’s antibody

Shares in AC Immune rose more than 75% on the news that semorinemab met one of two study endpoints

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

Article

A glimmer of hope for Alzheimer’s patients, but at what cost?

Research Partnership

- PMLiVE

Biogen and Eisai present new data for controversial Alzheimer’s drug Aduhelm at AAIC

The data showed that high-dose Aduhelm treatment demonstrated consistent effects as measured by the Clinical Dementia Rating-Sum of Boxes

- PMLiVE

Roche engaged in talks with FDA for Alzheimer’s drug candidate

CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022

- PMLiVE

Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial

Trial will evaluate donanemab in participants at risk for cognitive and functional decline related to Alzheimer’s

- PMLiVE

FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm

Leaders maintain that Aduhelm fits into the regulatory paradigm of the FDA’s accelerated approval pathway

- PMLiVE

FDA acting commissioner Janet Woodcock requests independent review of Aduhelm approval

Approval of Biogen's Alzheimer's disease treatment has raised concerns over FDA staff interactions with the company

Biogen Idec building

FDA narrows label for Biogen’s Aduhelm to only include mild forms of Alzheimer’s disease

Reflects the patient population included in clinical trials of anti-amyloid treatment

- PMLiVE

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

The focus of the deal is two clinical-stage monoclonal antibodies in development for a number of neurodegenerative diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links